NeoGenomics Introduces Next-Generation Cancer Sequencing Tests

Fort Myers, Fla.-based NeoGenomics, a CLIA-certified laboratory that specializes in cancer genetics testing, has launched the first two of its next-generation cancer profiling tests for solid tumors and myelodysplastic syndrome, or MDS.

The lab’s MDS sequencing test analyzes plasma, bone marrow and peripheral blood samples and may allow patients to avoid bone marrow biopsies. The test covers 16 genes that regulate epigenomics, signal transduction, transcription regulation and spliceosomes.
The test also quantifies and monitors tumor load and may help accurately diagnose MDS in the difficult early stage of the disease, the company says.

The solid tumor test can be performed on paraffin-embedded tissue and covers 48 genes, including the driver genes involved in multiple types of solid tumor cancers.

NeoGenomics notes that because the tests cover a small number of genes, the results are more reliable than those of conventional sequencing technology.

The company’s other testing services cover cytogenetics, immunohistochemistry, morphology studies, flow cytometry, molecular genetics, anatomic pathology and fluorescence in-situ hybridization. — Lena Freund

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.